WASHINGTON, April 7 (Reuters) - U.S. health regulators warned Gilead Sciences, Biogen Idec and other drugmakers on Wednesday over misleading promotions for various products.
In letters to the companies, the U.S. Food and Drug Administration warned Gilead over a direct-to-consumer print advertisement for its HIV drug, Truvada. It also warned Biogen over a webcast touting its multiple sclerosis therapy, Tysabri.
The agency also issued a letter to privately held Aton Pharma Inc as well as a previously released warning letter to Salix Pharmaceuticals.
Representatives for Gilead and Biogen could not be immediately reached for comment. Keywords: FDA ADVERTISING/ (Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
In letters to the companies, the U.S. Food and Drug Administration warned Gilead over a direct-to-consumer print advertisement for its HIV drug, Truvada. It also warned Biogen over a webcast touting its multiple sclerosis therapy, Tysabri.
The agency also issued a letter to privately held Aton Pharma Inc as well as a previously released warning letter to Salix Pharmaceuticals.
Representatives for Gilead and Biogen could not be immediately reached for comment. Keywords: FDA ADVERTISING/ (Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.